TR200103612T2 - Tiazol ve oksazol türevleri ve farmasötik kullanımları - Google Patents

Tiazol ve oksazol türevleri ve farmasötik kullanımları

Info

Publication number
TR200103612T2
TR200103612T2 TR2001/03612T TR200103612T TR200103612T2 TR 200103612 T2 TR200103612 T2 TR 200103612T2 TR 2001/03612 T TR2001/03612 T TR 2001/03612T TR 200103612 T TR200103612 T TR 200103612T TR 200103612 T2 TR200103612 T2 TR 200103612T2
Authority
TR
Turkey
Prior art keywords
thiazole
oxazole derivatives
pharmaceutical uses
pharmaceutical
oxazole
Prior art date
Application number
TR2001/03612T
Other languages
English (en)
Inventor
Yu-Hsuan Chao Esther
Jeanne Gellibert Franco�Se
Dale Haffner Curt
Hurst Lambert Millard Iii
Reed Maloney Patrick
Lawrence Sierra Michael
David Sternbach Daniel
Luis Sznaidman Marcos
Mark Willson Timothy
Eric Xu Huaqiang
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of TR200103612T2 publication Critical patent/TR200103612T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Formül (I) bilesik tarif edilmektedir. Bu bilesikler insan PPAR delta seçici aktiflestiricilerini içerir.
TR2001/03612T 1999-06-25 2000-06-22 Tiazol ve oksazol türevleri ve farmasötik kullanımları TR200103612T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9914977.5A GB9914977D0 (en) 1999-06-25 1999-06-25 Chemical compounds

Publications (1)

Publication Number Publication Date
TR200103612T2 true TR200103612T2 (tr) 2002-05-21

Family

ID=10856125

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/03612T TR200103612T2 (tr) 1999-06-25 2000-06-22 Tiazol ve oksazol türevleri ve farmasötik kullanımları

Country Status (29)

Country Link
US (2) US6710063B1 (tr)
EP (1) EP1189895B8 (tr)
JP (2) JP3490704B2 (tr)
KR (1) KR100668026B1 (tr)
CN (1) CN1164579C (tr)
AR (1) AR035320A1 (tr)
AT (1) ATE297384T1 (tr)
AU (1) AU765347B2 (tr)
BR (1) BR0011891A (tr)
CA (1) CA2377126C (tr)
CO (1) CO5180622A1 (tr)
CZ (1) CZ300654B6 (tr)
DE (1) DE60020701T2 (tr)
ES (1) ES2243276T3 (tr)
GB (1) GB9914977D0 (tr)
HK (1) HK1042897B (tr)
HU (1) HUP0201858A3 (tr)
IL (2) IL146634A0 (tr)
MX (1) MXPA01013244A (tr)
MY (1) MY120090A (tr)
NO (1) NO321872B1 (tr)
NZ (1) NZ515676A (tr)
PE (1) PE20010406A1 (tr)
PL (1) PL353135A1 (tr)
PT (1) PT1189895E (tr)
TR (1) TR200103612T2 (tr)
TW (1) TWI256389B (tr)
WO (1) WO2001000603A1 (tr)
ZA (1) ZA200109804B (tr)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0024361D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
GB0024362D0 (en) * 2000-10-05 2000-11-22 Glaxo Group Ltd Medicaments
UA82048C2 (uk) 2000-11-10 2008-03-11 Эли Лилли Энд Компани Агоністи альфа-рецепторів, активованих проліфератором пероксисом
GB0031103D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
GB0031109D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
US20040072838A1 (en) 2000-12-20 2004-04-15 Pierette Banker Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors
JP2004517100A (ja) 2000-12-20 2004-06-10 グラクソ　グループ　リミテッド ｈＰＰＡＲアルファアゴニストとしての置換オキサゾールおよびチアゾール
GB0031107D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
US7105551B2 (en) 2000-12-20 2006-09-12 Smithkline Beecham Corporation Thiazole derivatives for treating PPAR related disorders
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
AU2002243778A1 (en) * 2001-02-02 2002-09-19 Smithkline Beecham Corporation Treatment of ppar mediated diseases
JP4157381B2 (ja) * 2001-03-23 2008-10-01 日本ケミファ株式会社 ペルオキシソーム増殖剤応答性受容体の活性化剤
US20030077298A1 (en) * 2001-04-13 2003-04-24 The Regents Of The University Of California, A California Corporation Activators and ligands of PPAR-beta/delta for the treatment of skin conditions
MXPA03010435A (es) * 2001-05-15 2004-03-09 Hoffmann La Roche Derivados de oxazol acido carboxilico sustituidos para uso como activadores de proliferacion del peroximosa(ppar-alfa y gama) en el tratamiento de diabetes.
GB0113231D0 (en) * 2001-05-31 2001-07-25 Glaxo Group Ltd Chemical compounds
DE60234348D1 (de) 2001-07-17 2009-12-24 Teijin Ltd Selektionsverfahren für eine durch das austesten einer ppard aktivierenden wirkung charakterisierten substanz und arzneistoff
US7067530B2 (en) 2001-07-30 2006-06-27 Novo Nordisk A/S Compounds, their preparation and use
US6869967B2 (en) 2001-07-30 2005-03-22 Novo Nordisk A/S Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives
PT1424330E (pt) * 2001-08-10 2011-12-22 Nippon Chemiphar Co Activador do receptor ä responsivo a proliferadores peroxissomais
IL160845A0 (en) * 2001-09-14 2004-08-31 Tularik Inc Linked biaryl compounds
US7220877B2 (en) 2001-10-17 2007-05-22 Novo Nordisk A/S Compounds, their preparation and use
DE60315603T2 (de) * 2002-02-25 2008-05-21 Eli Lilly And Co., Indianapolis Modulatoren von peroxisome proliferator-aktivierten rezeptoren
WO2003072102A1 (en) 2002-02-25 2003-09-04 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
EP1478630A2 (en) * 2002-02-28 2004-11-24 SmithKline Beecham Corporation Process and intermediates for preparing phenylthiomethyl-thiazoles or -oxazoles
EP1480957A1 (en) 2002-03-01 2004-12-01 Smithkline Beecham Corporation Hppars activators
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
US20030207924A1 (en) * 2002-03-07 2003-11-06 Xue-Min Cheng Compounds that modulate PPAR activity and methods of preparation
US6833380B2 (en) * 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6716842B2 (en) * 2002-04-05 2004-04-06 Warner-Lambert Company, Llc Antidiabetic agents
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
KR100474202B1 (ko) 2002-05-04 2005-03-08 강헌중 티아졸 유도체의 제조방법 및 이를 제조하기 위한 중간체
US20060148858A1 (en) * 2002-05-24 2006-07-06 Tsuyoshi Maekawa 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity
JP2004277397A (ja) * 2002-05-24 2004-10-07 Takeda Chem Ind Ltd １，２−アゾール誘導体
WO2004005266A1 (en) * 2002-07-03 2004-01-15 F. Hoffmann-La Roche Ag Oxazole derivatives and their use as insulin sensitizers
NZ537251A (en) * 2002-07-09 2007-02-23 Bristol Myers Squibb Co Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
EP1537091B1 (en) * 2002-08-30 2010-10-06 F. Hoffmann-La Roche AG Novel 2-arylthiazole compounds as pparalpha and ppargamma agonists
CN1688540A (zh) 2002-09-05 2005-10-26 诺沃挪第克公司 新颖的乙烯基羧酸衍生物以及它们的治疗用途
AU2003262023A1 (en) * 2002-09-10 2004-04-30 Takeda Pharmaceutical Company Limited Five-membered heterocyclic compounds
JP2004123732A (ja) * 2002-09-10 2004-04-22 Takeda Chem Ind Ltd ５員複素環化合物
CN100577660C (zh) 2002-09-12 2010-01-06 霍夫曼-拉罗奇有限公司 作为ppar激动剂用于治疗糖尿病的n-取代-1h-吲哚-5-丙酸化合物
US7162262B2 (en) 2002-09-23 2007-01-09 Telefonaktiebolaget Lm Ericsson (Publ) Methods, systems and computer program products for requesting received power levels based on received block error rates utilizing an anti-windup and/or emergency procedure
US20050080115A1 (en) 2002-10-28 2005-04-14 Lone Jeppesen Novel compounds, their preparation and use
US7129268B2 (en) 2002-10-28 2006-10-31 Novo Nordisk A/S Peroxisome proliferator activated receptor-active arylene acetic acid derivatives
KR20050055790A (ko) 2002-10-28 2005-06-13 노보 노르디스크 에이/에스 Ｐｐａｒ 매개 질환의 치료에 유용한 신규 화합물
PL376718A1 (pl) 2002-10-28 2006-01-09 Novo Nordisk A/S Nowe związki, ich wytwarzanie i stosowanie
EP2385032A1 (en) * 2002-11-08 2011-11-09 Takeda Pharmaceutical Company Limited GPR40 Receptor function regulator
ES2312819T3 (es) 2002-11-25 2009-03-01 F. Hoffmann-La Roche Ag Derivados de indolilo.
US7816385B2 (en) 2002-12-20 2010-10-19 High Point Pharmaceuticals, Llc Dimeric dicarboxylic acid derivatives, their preparation and use
US7384965B2 (en) 2003-01-06 2008-06-10 Eli Lilly And Company Fused heterocyclic derivatives as PPAR modulators
DE10308354A1 (de) * 2003-02-27 2004-12-23 Aventis Pharma Deutschland Gmbh Cycloalkylderivate mit biosteren Carbonsäure-Gruppen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7148246B2 (en) * 2003-02-27 2006-12-12 Sanofi-Aventis Deutschland Gmbh Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
US6987118B2 (en) 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
EP1670744B9 (en) 2003-09-19 2012-09-05 Janssen Pharmaceutica NV 4-((phenoxyalkyl)thio)-phenoxyacetic aci ds and analogs
JP4928941B2 (ja) 2003-09-19 2012-05-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ４−（（フェノキシアルキル）チオ）−フェノキシ酢酸および類似化合物
NZ546031A (en) 2003-09-22 2009-03-31 Ono Pharmaceutical Co Phenylacetic acid derivative, process for producing the same, and use
JP4922615B2 (ja) 2003-11-26 2012-04-25 武田薬品工業株式会社 受容体機能調節剤
WO2005060958A1 (en) * 2003-12-19 2005-07-07 Kalypsys, Inc. (5- (2-phenyl)-thiazol-5-ylmethoxy)-indol-1-yl) -acetic acid derivatives and related compounds as modulators of the human ppar-delta receptor for the treatment of metabolic disorders such as type 2 diabetes
TW200523247A (en) 2003-12-25 2005-07-16 Takeda Pharmaceutical 3-(4-benzyloxyphenyl) propanoic acid derivatives
WO2005063725A1 (ja) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited フェニルプロパン酸誘導体
EP1737809B1 (en) 2004-02-27 2013-09-18 Amgen, Inc Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
BRPI0509540A (pt) * 2004-04-01 2007-09-18 Aventis Pharma Inc uso de agonistas do receptor delta ativado pelo proliferador de peroxissoma para o tratamento de ms e outras doenças desmielinizantes
RU2365589C2 (ru) * 2004-04-01 2009-08-27 Авентис Фармасьютикалз Инк. 1,3,4-оксадиазол-2-оны в качестве модуляторов ppar-дельта, фармацевтические композиции на их основе и способ лечения
DE602004004631D1 (de) 2004-04-01 2007-03-22 Sanofi Aventis Deutschland Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika
CA2561738A1 (en) * 2004-04-01 2005-10-20 Aventis Pharmaceuticals Inc. 1,3,4-oxadiazol-2-ones as ppar delta modulators_and their use thereof
WO2005105736A1 (en) 2004-05-05 2005-11-10 Novo Nordisk A/S Novel compounds, their preparation and use
ES2352085T3 (es) 2004-05-05 2011-02-15 High Point Pharmaceuticals, Llc Nuevos compuestos, su preparación y uso.
PE20060315A1 (es) * 2004-05-24 2006-05-15 Irm Llc Compuestos de tiazol como moduladores de ppar
US20060014785A1 (en) * 2004-05-25 2006-01-19 Metabolex, Inc. Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
WO2005115383A2 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Substituted triazoles as modulators of ppar and methods of their preparation
JP2007269630A (ja) * 2004-06-23 2007-10-18 Toudai Tlo Ltd インスリン分泌促進剤
MY147518A (en) 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
WO2006043797A1 (en) * 2004-10-22 2006-04-27 Heonjoong Kang Process for alkyl aryl sulfide derivatives and new sulfide compounds
EP1819681B1 (en) * 2004-11-23 2009-08-12 Warner-Lambert Company LLC 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia
WO2006057448A1 (ja) * 2004-11-26 2006-06-01 Takeda Pharmaceutical Company Limited アリールアルカン酸誘導体
WO2006071103A1 (en) * 2004-12-31 2006-07-06 Heonjoong Kang Organoselenium containing compounds and their use
KR100753860B1 (ko) * 2004-12-31 2007-08-31 재단법인서울대학교산학협력재단 유기 셀레늄 함유 화합물 및 이들 화합물의 용도
FR2880886B1 (fr) * 2005-01-14 2007-04-06 Merck Sante Soc Par Actions Si Derives de l'acide 6-phenylhex-5-enoique, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique
US20090054493A1 (en) * 2005-02-25 2009-02-26 Heonjoong Kang Kang Thiazole derivatives as ppar delta ligands and their manufacturing process
CN101193876B (zh) * 2005-05-07 2011-05-11 财团法人首尔大学校产学协力财团 制备PPARδ的配体的方法和用于制备该配体的中间化合物
US7465804B2 (en) * 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
EP1887000A4 (en) 2005-05-27 2011-09-07 Shionogi & Co ARYLACETATE DERIVATIVES WITH ISOXAZO EASY
US20090137614A1 (en) * 2005-05-27 2009-05-28 Shionogi & Co., Ltd. Pharmaceutical combination comprising vitamin k
BRPI0612730A2 (pt) 2005-06-30 2010-11-30 Novo Nordisk As compostos, suas preparações e uso
WO2007033002A1 (en) 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
CN101272784A (zh) 2005-09-29 2008-09-24 塞诺菲-安万特股份有限公司 苯基-和吡啶基-1,2,4-噁二唑酮衍生物、它们的制备方法和它们作为药物的用途
PL1931660T3 (pl) 2005-09-29 2012-12-31 Sanofi Sa Pochodne fenylo-[1,2,4]-oksadiazol-5-onu z grupą fenylową, sposoby ich wytwarzania i ich zastosowanie jako środków farmaceutycznych
US7943613B2 (en) 2005-12-22 2011-05-17 High Point Pharmaceuticals, Llc Compounds, their preparation and use
CN101400663A (zh) * 2006-01-10 2009-04-01 史密丝克莱恩比彻姆公司 {2-甲基-4-[4-甲基-2-(4-三氟甲基苯基)噻唑-5-基甲硫基]苯氧基}-乙酸的多晶型
CN101007790B (zh) * 2006-01-27 2011-03-30 北京摩力克科技有限公司 草氨酸衍生物、其制备方法和医药用途
CN101374834B (zh) * 2006-02-03 2011-12-14 伊莱利利公司 用于调节fxr的化合物和方法
JP2009132620A (ja) * 2006-03-07 2009-06-18 Astellas Pharma Inc フェニルチアゾール誘導体
WO2007101864A2 (en) 2006-03-09 2007-09-13 High Point Pharmaceuticals, Llc Compounds that modulate ppar activity, their preparation and use
JP2009530281A (ja) * 2006-03-14 2009-08-27 アムジエン・インコーポレーテツド 代謝障害の治療に有用である二環式カルボン酸誘導体
PE20080188A1 (es) 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
EP2014652B1 (en) * 2006-04-18 2014-08-06 Nippon Chemiphar Co., Ltd. Activating agent for peroxisome proliferator activated receptor
US20100197950A1 (en) * 2006-06-08 2010-08-05 Kaare Gyberg Rasmussen Process for preparing phenoxy acetic acid derivatives
US20080004281A1 (en) * 2006-06-28 2008-01-03 Kalypsys, Inc. Methods for the modulation of crp by the selective modulation of ppar delta
JPWO2008016175A1 (ja) * 2006-08-03 2009-12-24 日本ケミファ株式会社 ペルオキシソーム増殖剤活性化受容体の活性化剤
US7687526B2 (en) 2006-09-07 2010-03-30 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
WO2008030520A1 (en) 2006-09-07 2008-03-13 Amgen Inc. Heterocyclic gpr40 modulators
EP2061484B1 (en) 2006-09-08 2012-11-07 Rhode Island Hospital Treatment, prevention, and reversal of alcohol-induced liver disease
JP2010502719A (ja) 2006-09-08 2010-01-28 ロード アイランド ホスピタル アルコール誘発性脳疾患の治療、予防および回復
CN102584685A (zh) 2006-12-02 2012-07-18 财团法人首尔大学校产学协力财团 作为ppar配体的芳基化合物及其用途
JP2010514804A (ja) 2006-12-29 2010-05-06 ザ・ソーク・インスティチュート・フォー・バイオロジカル・スタディーズ 運動能力を高めるための方法
US8236831B2 (en) 2007-01-08 2012-08-07 Seoul National University Industry Foundation Thiazole compound (as PPARδ) ligand and pharmaceutical, cosmetic and health food comprised thereof
WO2008103501A1 (en) * 2007-02-22 2008-08-28 Irm Llc Compounds and methods for modulating g protein-coupled receptors
US7572934B2 (en) 2007-04-16 2009-08-11 Amgen Inc. Substituted biphenyl GPR40 modulators
WO2008154023A1 (en) * 2007-06-11 2008-12-18 Cerenis Therapeutics S.A. Novel uses of ppar delta agonists
GB0712653D0 (en) 2007-06-28 2007-08-08 Syngenta Ltd Novel herbicides
GB0717082D0 (en) 2007-09-03 2007-10-10 Syngenta Ltd Novel herbicides
WO2009048527A1 (en) 2007-10-10 2009-04-16 Amgen Inc. Substituted biphenyl gpr40 modulators
AU2008338963A1 (en) * 2007-12-13 2009-06-25 Sri International PPAR-delta ligands and methods of their use
JP2011515341A (ja) * 2008-03-06 2011-05-19 アムジエン・インコーポレーテツド 代謝障害の治療に有用な立体配座的に制限されたカルボン酸誘導体
RU2501794C2 (ru) 2008-04-15 2013-12-20 Ниппон Кемифар Ко., Лтд. Активирующий агент для рецептора, активируемого стимулирующими рост пероксисом агентами
CN101643451B (zh) 2008-08-07 2013-03-06 浙江海正药业股份有限公司 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法
AU2009303475B2 (en) 2008-10-15 2012-09-13 Amgen Inc. Spirocyclic GPR40 modulators
WO2010045361A1 (en) 2008-10-17 2010-04-22 Metabolex, Inc. Methods of reducing small, dense ldl particles
WO2011105643A1 (ko) * 2010-02-25 2011-09-01 서울대학교산학협력단 퍼록시솜 증식자 활성화 수용체 리간드 셀레나졸 유도체, 이의 제조방법 및 이들 화합물의 용도
CN102285933B (zh) * 2010-06-18 2016-03-09 浙江海正药业股份有限公司 一种对亚型过氧化物酶增殖物激活受体具有激动作用的化合物、其制备方法和应用
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
JP2013538215A (ja) * 2010-08-31 2013-10-10 エスエヌユー アールアンドディービー ファウンデーション ＰＰＡＲδアゴニストの胎児再プログラミング用途
US9695137B2 (en) * 2013-03-14 2017-07-04 The University Of Toledo Analogs of peroxisome proliferator activated receptor (PPAR) agonists, and methods of using the same
US10181018B2 (en) * 2013-03-14 2019-01-15 The University Of Toledo Analogs of proxisome proliferator activated receptor (PPAR) agonists and methods of using the same
CA2923422C (en) 2013-09-09 2021-09-07 Vtv Therapeutics Llc Use of a ppar-delta agonist for treating muscle atrophy
WO2020085393A1 (ja) 2018-10-23 2020-04-30 国立研究開発法人科学技術振興機構 ＰＰＡＲδ活性化剤
US11634387B2 (en) 2019-09-26 2023-04-25 Abionyx Pharma Sa Compounds useful for treating liver diseases
WO2022189856A1 (en) * 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS644688A (en) * 1987-06-26 1989-01-09 Tokuyama Soda Kk Photochromic composition
JPH0793082B2 (ja) * 1987-09-07 1995-10-09 株式会社明電舎 真空インタラプタの化成方法
JP2551151B2 (ja) * 1989-06-22 1996-11-06 神鋼電機株式会社 潜熱回収方式の給湯装置における放熱装置
JP3039009B2 (ja) * 1991-06-25 2000-05-08 ソニー株式会社 固体撮像素子の駆動装置
TW268952B (tr) 1993-02-26 1996-01-21 Takeda Pharm Industry Co Ltd
JP3466273B2 (ja) 1993-06-11 2003-11-10 武田薬品工業株式会社 テトラゾール誘導体、その製造法およびそれを含んでなる医薬
US5591862A (en) * 1993-06-11 1997-01-07 Takeda Chemical Industries, Ltd. Tetrazole derivatives, their production and use
JP3836521B2 (ja) 1994-08-10 2006-10-25 武田薬品工業株式会社 ２，４−チアゾリジンジオン誘導体、その製造法およびそれを含んでなる医薬組成物
JP3880108B2 (ja) 1994-11-02 2007-02-14 武田薬品工業株式会社 ２，４−オキサゾリジンジオン誘導体、その製造法およびそれを含んでなる医薬組成物
JP2850809B2 (ja) 1994-11-02 1999-01-27 武田薬品工業株式会社 ２，４−オキサゾリジンジオン誘導体およびそれを含んでなる医薬組成物
JPH08325263A (ja) * 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd 新規２−アミノ−３−フェニルプロピオン酸誘導体
JPH08325250A (ja) * 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd 新規置換フェノール誘導体
US5859051A (en) * 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
WO1997028149A1 (en) 1996-02-02 1997-08-07 Merck & Co., Inc. Method for raising hdl cholesterol levels
US5847008A (en) 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
JP3215048B2 (ja) 1996-04-03 2001-10-02 日本たばこ産業株式会社 プロピオン酸誘導体及びその用途
WO1998007699A1 (fr) * 1996-08-19 1998-02-26 Japan Tobacco Inc. Derives d'acide propionique et applications de ces derives
JP4427825B2 (ja) * 1997-07-24 2010-03-10 アステラス製薬株式会社 コレステロール低下作用を有する医薬組成物
ATE451346T1 (de) * 1998-03-10 2009-12-15 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
KR102220553B1 (ko) * 2015-03-10 2021-02-26 한국전자통신연구원 표시 패널 및 그것을 포함하는 표시 장치

Also Published As

Publication number Publication date
CA2377126A1 (en) 2001-01-04
WO2001000603A1 (en) 2001-01-04
PT1189895E (pt) 2005-10-31
DE60020701T2 (de) 2006-05-04
HUP0201858A3 (en) 2004-12-28
CO5180622A1 (es) 2002-07-30
NO20016078D0 (no) 2001-12-13
JP2003313141A (ja) 2003-11-06
CN1358179A (zh) 2002-07-10
MY120090A (en) 2005-08-30
US6710063B1 (en) 2004-03-23
PL353135A1 (en) 2003-10-20
NO20016078L (no) 2001-12-13
AR035320A1 (es) 2004-05-12
AU765347B2 (en) 2003-09-18
TWI256389B (en) 2006-06-11
CZ20014664A3 (cs) 2002-03-13
AU5817100A (en) 2001-01-31
IL146634A (en) 2007-10-31
EP1189895B1 (en) 2005-06-08
ZA200109804B (en) 2003-02-28
ATE297384T1 (de) 2005-06-15
EP1189895B8 (en) 2005-11-09
HK1042897A1 (en) 2002-08-30
KR100668026B1 (ko) 2007-02-28
KR20020015358A (ko) 2002-02-27
BR0011891A (pt) 2002-03-05
EP1189895A1 (en) 2002-03-27
CN1164579C (zh) 2004-09-01
JP3490704B2 (ja) 2004-01-26
PE20010406A1 (es) 2001-04-10
GB9914977D0 (en) 1999-08-25
US6723740B2 (en) 2004-04-20
US20030203947A1 (en) 2003-10-30
DE60020701D1 (de) 2005-07-14
ES2243276T3 (es) 2005-12-01
NO321872B1 (no) 2006-07-17
HUP0201858A2 (en) 2002-09-28
CA2377126C (en) 2009-01-27
IL146634A0 (en) 2002-07-25
JP2003503399A (ja) 2003-01-28
HK1042897B (zh) 2005-12-02
NZ515676A (en) 2004-05-28
CZ300654B6 (cs) 2009-07-08
MXPA01013244A (es) 2002-07-02

Similar Documents

Publication Publication Date Title
TR200103612T2 (tr) Tiazol ve oksazol türevleri ve farmasötik kullanımları
NO20010628L (no) Substituerte oksazol- og thiazolderivater som hPPAR <gamma> og hPPAR <alfa> aktivatorer
DK1244642T3 (da) Substituerede oxazol- og thiazolderivater som HPPAR-alfa-aktivatorer
DK0513387T3 (da) Thiazolderivater som inhibitorer af aktivt oxygen
PT1193270E (pt) Pirrolobenzodiazepinas
NO20004192D0 (no) N-(Substituerte fem-leddete di- eller triaza di-umettede ring)karbonyl) guanidinderivater for behandling av ischemi
ATE302775T1 (de) Carbolinderivate
MY136141A (en) Novel hydantoin derivatives and pharmaceutical compositions useful as metalloproteinase inhibitors
AU2910600A (en) Phenyl urea and phenyl thiourea derivatives
TR200000059T2 (tr) Piridin türevleri
DK0449216T3 (da) 3,5-Di-tertiærbutyl-4-hydroxyphenylmethylenderivater af 2-substituerede thiazolidinoner, oxazolidinoner og imidazolidinoner som antiinflammatoriske midler
ES2191208T3 (es) Oxiimino-pregnano-carbolactonas.
DK1349843T3 (da) Thiazol- og oxazolderivater som aktivatorer af human peroxisom profilerator-aktiverede receptorer
ATE215938T1 (de) Serin-protease-inhibitoren: derivate des isothiazolidin-3-on-1,1-dioxids und des 3-oxo-1,2,5-thiadiazolidin-1,1-dioxids
ATE346067T1 (de) Carbolinderivate
NO992226D0 (no) Nye forbindelser for anvendelse som neuro-protektive midler
NO934628L (no) Retrovirus-protease-inhibitorer
ATE273007T1 (de) Behandlung der schizophrenie und der psychose
ATE259813T1 (de) Triazolopyrimidinderivate
DK0652874T3 (da) 2-heterocycliske-5-hydroxy-1,3-pyrimidiner der er nyttige som antiinflammatoriske midler
DE60128100D1 (de) Analgetisches arzneimittel
TR200000637T2 (tr) Benzoksazin ve benzotiazin türevleri ve bunların ilaçlarda kullanımı.
NO20035209D0 (no) Oksazol/Tiazol-derivataktivatorer av HPPAR-alfa reseptoren
ATE330958T1 (de) Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate
UY26416A1 (es) Compuestos